Orexo has been granted a patent for a solid pharmaceutical composition in powder form for nasal delivery of an opioid antagonist, naloxone. The composition includes naloxone, a disaccharide, and a dextrin, suitable for treating opioid overdose. The patent ensures stability and effectiveness of the formulation. GlobalData’s report on Orexo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orexo, Cancer treatment biomarkers was a key innovation area identified from patents. Orexo's grant share as of February 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for nasal delivery of opioid antagonist
A recently granted patent (Publication Number: US11883392B2) discloses a solid pharmaceutical composition in the form of a spray-dried powder designed for nasal delivery of naloxone or its pharmaceutically-acceptable salt. The composition, free of water, includes a combination of a disaccharide (such as maltitol, trehalose, or lactose) and a dextrin as carrier materials. The patent highlights the stability of the naloxone component, with less than 15% chemical degradation observed after 3 months of storage at 75% relative humidity and 40°C. Additionally, the composition's glass transition temperature, particle size distribution, and specific ingredients like alkyl saccharides are detailed to ensure optimal performance.
Moreover, the patent covers the manufacturing process of the pharmaceutical composition, involving the mixing of naloxone with carrier materials in a volatile solvent and subsequent spray-drying to form the desired powder. The patent also extends to a nasal applicator device suitable for delivering the composition to the nose, emphasizing the importance of packaging within containers that prevent the ingress of atmospheric water under specified storage conditions. The method of treating opioid overdose using the disclosed composition, along with variations in water content and chemical degradation levels of naloxone, are also outlined in the patent claims, underscoring the innovation and specificity of the pharmaceutical formulation and delivery system.
To know more about GlobalData’s detailed insights on Orexo, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
